Trabectedin Plus Pegylated Liposomal Doxorubicin: The Return of a Treatment Option foR Ovarian Cancer

Abstract

Future OncologyVol. 9, No. 12s ForewordFree AccessTrabectedin plus pegylated liposomal doxorubicin: the return of a treatment option for ovarian cancerJohn ClareJohn ClareLion's Den Communications Ltd, London, UK. Search for more papers by this authorEmail the corresponding author at john.clare@lionsdencommunications.comPublished Online:6 Nov 2013https://doi.org/10.2217/fon.13.203AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit Keywords: fully platinum-sensitiveovarian cancerpartially platinum-sensitivepegylated liposomal doxorubicintrabectedinManufacturing difficulties resulted in a shortage of pegylated liposomal doxorubicin (PLD), but these problems have recently been resolved and PLD is now available again. It follows that oncologists now have access to this important anticancer therapy and the combination of trabectedin (Yondelis®, PharmaMar, Madrid, Spain) plus PLD can once more be prescribed for the treatment of relapsed ovarian cancer, the topic under discussion at this symposium.Today we have a much greater understanding regarding which patients with ovarian cancer in particular will benefit the most from treatment with trabectedin plus PLD: ▪ The first group involves patients with partially platinum-sensitive disease;▪ The second group includes patients fully platinum-sensitive but who, for whatever reason, cannot be retreated with platinum therapy.These are important clinical problems that oncologists have to deal with in their daily practice and in this symposium we count on eminent experts in the field to present some of the most recent data on these topics under the chairmanship of Andres Poveda (Instituto Valenciano de Oncología, Valencia, Spain) and Eric Pujade-Lauraine (Hôpital Hôtel-Dieu, París, France). Key speakers at the symposium are Nicoletta Colombo (European Institute of Oncology, University of Milan, Bicocca, Milan, Italy), Maurizio D‘Incalci (IRCCS – Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy), Antonio González (MD Anderson Cancer Center, Madrid, Spain) and Isabel Ray-Coquard (Centre Léon Bérard, Lyon, France). To discuss the findings that are presented with the goal of providing an overall perspective we have the following experts: Jalid Sehouli (European Competence Center for Ovarian Cancer, Charité University Hospital, Berlin, Germany), Josep M del Campo (Vall d‘Hebron University Hospital, Barcelona, Spain) and Domenica Lorusso (Fondazione `IRCCS‘ National Cancer Institute, Milan, Italy).Financial & competing interests disclosureThe author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Editorial assistance was provided by Content Ed Net, with funding from PharmaMar, Madrid, Spain.FiguresReferencesRelatedDetails Vol. 9, No. 12s eToC Sign up Follow us on social media for the latest updates Metrics History Published online 6 November 2013 Published in print December 2013 Information© Future Medicine LtdKeywordsfully platinum-sensitiveovarian cancerpartially platinum-sensitivepegylated liposomal doxorubicintrabectedinFinancial & competing interests disclosureThe author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Editorial assistance was provided by Content Ed Net, with funding from PharmaMar, Madrid, Spain.PDF download